Skip to content

Effect of intense pulsed light (IPL) technology in treating dry eye

Effect of intense pulsed light technology in treating Meibomian Gland Dysfunction (MGD)

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12614000162617
Enrollment
28
Registered
2014-02-10
Start date
2014-01-06
Completion date
2014-02-07
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

To identify changes to the tear film and ocular surface in participants with meibomian gland dysfunction, in response to 3 treatments (on Days 1, 15 and 45) with intense pulsed light (E>Eye, France Medical Ltd Pty, Aust)

Interventions

At each visit, IPL is performed using a non-coherent, filtered broadband pulsed flash lamp (E>Eye, France Medical, Brisbane, Australia), at 9 - 13 J/cm^2 (according to skin type), in four pulses per eye (manufacturer's proprietary pulse profile), below the lower eyelid from the outer to inner canthus, while metal light-blocking goggles are worn to protect globe. Treatments are performed on Day 1, Day 15 and Day 45, with treatment duration of approximately 20 seconds.

Sponsors

The University of Auckland
Lead SponsorUniversity

Study design

Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used) (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
All
Age
16 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Dry eye symptoms (OSDI) and clinical evidence of Meibomian gland dysfunction by meibography

Exclusion criteria

Other anterior segment pathology Any conditions which preclude treatment by IPL

Outcome results

None listed

Source: ANZCTR · Data processed: Mar 5, 2026